Prise en charge du diabète au Luxembourg en 2017 – Version longue

Objectives

Provide updated, evidence-graded and patient-centred recommendations for comprehensive diabetes care in Luxembourg, standardising practice for healthcare professionals while supporting people with diabetes and their families to manage the condition throughout life. The framework covers type 1 diabetes, type 2 diabetes, diabetes in pregnancy, hypoglycaemia and diabetic ketoacidosis, and seeks to optimise existing care structures and financial resources.[1][2][3]

• Strengthen early identification and prevention of type 2 diabetes by recognising prediabetes and risk factors, using validated risk-assessment and diagnostic tools, and supporting sustained lifestyle improvement.[4][5][6]
• Achieve and maintain individualised glycaemic control while preventing acute complications, including hypoglycaemia and ketoacidosis, and reducing long-term cardiovascular, renal, neurological and ocular complications.[7][8][9]
• Embed therapeutic education and self-management support in care, enabling people to understand treatment targets, administer and adjust treatment where appropriate, monitor glucose, respond to acute problems and maintain a healthy lifestyle.[10][11][12]
• Deliver individualised care that accounts for comorbidities, complications, life stage, family and social context, psychological wellbeing, personal preferences and treatment adherence.[2][9][13]
• Promote healthy eating, weight management and regular physical activity as core elements of prevention and diabetes management.[14][15][16][17]
• Protect maternal and fetal health through pregnancy planning, pre-conception counselling, near-normal glycaemic control where safely achievable, specialised pregnancy care and screening for diabetes-related risks.[18][19]
• Prevent and detect complications through systematic attention to neuropathy, diabetic foot disease, nephropathy and retinopathy, alongside cardiovascular risk-factor management.[20][21][22][23]
• Apply transparent evidence grading, distinguishing strong, weak or absent recommendations and high, intermediate or low levels of scientific evidence.[24]

Implementation

Organise delivery around lifelong, multidisciplinary and increasingly personalised clinical care, combining structured assessment, therapeutic education, self-monitoring, lifestyle support, medicines and technology with specialist referral when required. The recommendations were developed through a working group under Luxembourg’s Scientific Council for Health, drawing substantially on American Diabetes Association guidance while permitting locally formulated recommendations.[1][24][3]

• Coordinate dissemination through the Minister of Health, Luxembourg Diabetes Association and Scientific Council, while using the Scientific Council’s multidisciplinary diabetes working group to develop and adopt recommendations.[2][3]
• Provide regular initial and follow-up assessment for type 1 and type 2 diabetes, including medical history, clinical examination, biological testing, treatment review, self-management capacity, lifestyle, psychosocial circumstances and complication risks.[25][26][27]
• Deliver therapeutic education through trained professionals, adapting it to age, intellectual abilities, culture, individual objectives and family circumstances; involve parents, relatives, schools and other support networks where appropriate.[10][28][12]
• Use multidisciplinary teams that may include diabetologists, specialised nurses, dietitians, psychologists or psychotherapists, podiatrists or medical pedicurists and social workers; maintain regular contact, including at least quarterly in paediatric care and twice yearly in adult care.[28]
• Use selective glucose self-monitoring and diabetes technologies according to treatment intensity, hypoglycaemia risk, pregnancy, illness, physical activity and the person’s ability and motivation to use results to adjust treatment.[29][30][11]
• Screen people at elevated risk of type 2 diabetes using the Finnish Diabetes Risk Score, confirm abnormal screening findings through validated venous glucose, glycated haemoglobin or oral glucose-tolerance testing, and repeat screening according to age and risk profile.[5][31][32]
• Match pharmacological treatment to individual glycaemic targets, comorbidities, hypoglycaemia risk, weight effects, adverse effects and preferences; use metformin where appropriate and intensify treatment without delay when targets are unmet.[9][33]
• Provide specialised pathways for pregnancy, diabetic ketoacidosis, severe hypoglycaemia, neuropathy and diabetic foot disease, kidney disease and retinopathy, including hospitalisation or specialist referral where clinical criteria warrant this.[34][35][36][37][38]
• Monitor care through clinical measures and scheduled reviews, including glucose and glycated haemoglobin, blood pressure, renal function and albuminuria, foot and neurological assessment, retinal examination, cardiovascular risk, nutrition, physical activity and psychological wellbeing.[39][27][21][22]
• Use follow-up of public-health indicators as an implementation principle, although the supplied material does not specify a full indicator set, reporting arrangements, evaluation timetable, accountability structure or dedicated implementation budget.[2]

Monitoring & Evaluation

Monitoring is principally clinical and embedded in lifelong, multidisciplinary diabetes care. The guideline uses evidence grading to distinguish strong, weak or absent recommendations and high, intermediate or low scientific evidence, while its broader implementation approach refers to follow-up of public-health indicators without defining a national indicator set, reporting cycle or accountable body.[1][2][24]

• Monitor population burden through reported prevalence estimates, including 6.5% for diabetes and 25.6% for prediabetes in Luxembourg, alongside estimates of undiagnosed type 2 diabetes.[40][4]
• Monitor type 1 diabetes through regular history-taking, clinical examination, biological tests, glycaemic self-monitoring and glycated haemoglobin measurement, with assessment of acute complications, self-management capacity, lifestyle, psychosocial circumstances and comorbidities.[41][25][39]
• Review glucose-management technology by assessing glycaemic results, self-management quality, hypoglycaemia frequency and awareness, adherence, motivation and capacity to use monitoring data to adjust treatment.[29][42][43]
• Evaluate therapeutic education through documented glucose measurements, injections, self-management skills and ongoing educational review; cited evidence associates education programmes with reductions in glycated haemoglobin of 0.3% to 1% in type 1 diabetes and 0.5% to 2% in type 2 diabetes.[10][28][12]
• Screen for type 2 diabetes using validated risk tools and biological tests, with repeat screening every three years for lower-risk adults over 45 and annually for people with elevated body mass index and additional risk factors.[31][32][6]
• Review type 2 diabetes at defined intervals, including glycated haemoglobin every six months when targets are met and treatment is unchanged, or every three months otherwise; assess lipids, renal function, albuminuria, cardiovascular and foot status, treatment adherence and social vulnerability.[44][27]
• Reassess pharmacological treatment every three to six months, intensifying or adjusting therapy when individual glycaemic targets are not achieved and considering periodic vitamin B12 testing during long-term metformin treatment.[9][33]
• Monitor pregnancy through frequent fasting and post-prandial glucose testing, glycated haemoglobin targets, retinal examinations before or early in pregnancy and each trimester, post-partum eye follow-up, and renal and thyroid screening.[18][45][19]
• Monitor acute complications at patient level, including glucose reassessment 15 minutes after treatment for hypoglycaemia and clinical and biochemical assessment of suspected diabetic ketoacidosis.[46][35][47]
• Screen for complications through scheduled neuropathy and foot examinations, annual or risk-based vascular assessment, renal albumin-to-creatinine ratio and estimated glomerular filtration rate testing, and ophthalmological surveillance tailored to diabetes type, duration, pregnancy and previous findings.[21][48][49][22][50][23]
• Assess nutrition, physical activity and psychosocial wellbeing through annual weight and dietary review, glucose monitoring around exercise where indicated, and regular assessment of psychological development, mental health, family supervision, anxiety, depression and social barriers.[15][16][51][52][53][13][54]

Across the supplied material, monitoring arrangements are predominantly individual clinical assessments rather than a formal programme evaluation system. The guideline does not specify routine national reporting, audit procedures, a surveillance architecture, quantified performance targets, an evaluation timetable or clear accountability mechanisms.[2][24][27][23]

Costing & Financing

Financing information is limited. The only quantified national estimate is that the International Diabetes Federation estimated Luxembourg’s diabetes-care expenditure at 180 million euros in 2014, equivalent to 7% of the health budget.[55]

• Optimise use of existing structures and financial resources as an objective of the recommendations, without setting a dedicated implementation budget, financing plan or allocation mechanism.[2]
• Recognise that early intervention for people at risk of diabetes can be economically cost-effective and that earlier care may reduce social-security expenditure related to treatment, follow-up and complications, although no quantified savings are provided.[4]
• Note that continuous glucose-monitoring sensors have become more reliable and less costly, supporting wider routine-care accessibility, but without reimbursement rules, unit costs or affordability estimates.[42]
• Consider cost limitation among treatment-selection objectives for type 2 diabetes, with sulphonylureas and thiazolidinediones identified as options where limiting costs is a principal aim.[20]
• Require trained multidisciplinary, nutritional, psychological, specialist and technology-support capacity across care pathways, but do not quantify staffing, equipment, service-delivery or training costs.[28][56][38]

No funding gaps, resource-mobilisation plan, reimbursement arrangement, budget breakdown, economic model, cost-effectiveness result, or programme-level financial accountability mechanism is specified beyond the expenditure estimate and qualitative references to efficient resource use.[2][4][57]